Evolent Health, INC Form 4 insider transactions

Evolent Health, Inc. Director Russell Monroe Glass was granted 21,979 restricted stock units (RSUs) as part of his compensation, vesting in 2026.

Evolent Health, Inc. Director Craig A. Barbarosh was granted 21,979 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Evolent Health, Inc. Director Peter J. Grua was granted 21,979 restricted stock units of Class A Common Stock, increasing his beneficial ownership in the company.

Evolent Health, Inc. (EVH) Director Kim Keck was granted 21,979 restricted stock units (RSUs) on June 5, 2025, as part of the company's incentive compensation plan.

Evolent Health, Inc. Director Toyin Ajayi was granted 21,979 restricted stock units, aligning executive compensation with future company performance.

Director Diane Holder reports purchasing 2,735 shares of Evolent Health, Inc. (EVH) at $9.33 per share on March 6, 2025.

Daniel Joseph McCarthy, President of Evolent Health, Inc., recently purchased 11,040 shares of Class A Common Stock at an average price of $9.01.

Richard Jelinek, a director of Evolent Health, Inc., recently purchased 30,000 shares of Class A Common Stock through revocable trusts at prices around $9.10 per share.

Director Peter Grua of Evolent Health, Inc. reports purchasing 11,040 shares of Class A Common Stock at an average price of $9.01 on March 6, 2025, increasing his total holdings.

Evolent Health's CEO, Seth Blackley, recently purchased 55,225 shares of Class A Common Stock at an average price of $9.01.

Director Brendan B Springstubb purchased 15,000 shares of Evolent Health, Inc. at an average price of $9.27 on March 7, 2025.

Director Russell Monroe Glass of Evolent Health, Inc. reports the acquisition of 5,400 shares of Class A Common Stock at $9.27 per share on March 6, 2025.

Director Kim Keck of Evolent Health, Inc. purchased 10,540 shares of Class A Common Stock at a weighted average price of $9.44 on March 7, 2025.

Director Craig A. Barbarosh of Evolent Health, Inc. recently acquired 2,000 shares of Class A Common Stock at a price of $8.81 per share.

Brendan B. Springstubb, a director at Evolent Health, Inc., reported the acquisition of shares and restricted stock units.

Emily Rafferty, COO of Evolent Health, reports acquisition and disposal of Class A Common Stock due to vesting of restricted stock units and performance-based share units.

Daniel McCarthy, President of Evolent Health, reports acquisition and disposal of Class A Common Stock, including shares withheld for tax obligations and vesting of restricted stock units.

Aammaad Shams, Chief Accounting Officer of Evolent Health, reports acquisition and disposal of Class A Common Stock due to vesting of restricted stock units and settlement of performance-based share units.

Jonathan Weinberg, General Counsel of Evolent Health, reports transactions involving Class A Common Stock, including acquisitions, disposals, and vesting of restricted stock units and performance-based share units.

Evolent Health's CEO, Seth Blackley, reports acquisition and disposal of Class A Common Stock due to vesting of restricted stock units and performance-based share units.

John Paul Johnson, CFO of Evolent Health, reports acquisition and disposal of Class A Common Stock due to vesting of restricted stock units and performance-based share units.

Daniel McCarthy, President of Evolent Health, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Jonathan Weinberg, General Counsel of Evolent Health, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Evolent Health's CEO, Seth Blackley, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan, while also adjusting his reported holdings due to a transfer of shares related to a domestic relations order.

Evolent Health's CFO, John Paul Johnson, sold 44,693 shares of Class A Common Stock at a weighted average price of $30.00 on August 22, 2024, under a pre-arranged 10b5-1 trading plan.

Emily Ann Rafferty, Chief Operating Officer of Evolent Health, Inc., sold 8,861 shares of Class A Common Stock on August 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Aammaad Shams, Chief Accounting Officer of Evolent Health, Inc., reports the disposal of shares to cover tax obligations upon vesting of restricted stock units.

Director Peter J. Grua of Evolent Health, Inc. reports acquisition of restricted stock units and changes in beneficial ownership.

Cheryl Scott, a director at Evolent Health, Inc., was granted 7,709 restricted stock units on June 6, 2024, under the company's 2015 Omnibus Incentive Compensation Plan.

Director Diane Holder received 7,709 restricted stock units of Evolent Health, Inc. on June 6, 2024, under the company's 2015 Omnibus Incentive Compensation Plan.